Methods for treating HCV
US-9452154-B2 · Sep 27, 2016 · US
Methods and compounds for treating paramyxoviridae virus infections
US10696679B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10696679-B2 |
| Application number | US-201816042085-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 23, 2018 |
| Priority date | Jul 22, 2010 |
| Publication date | Jun 30, 2020 |
| Grant date | Jun 30, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a Paramyxoviridae infection, comprising administering to a human subject in need thereof a therapeutically effective amount of a compound of Formula or a pharmaceutically acceptable salt or ester, thereof. 2. The method of claim 1 further comprising administering a therapeutically effective amount of at least one other therapeutic agent or composition thereof selected from the group consisting of a corticosteroid, an anti-inflammatory signal transduction modulator, a β2-adrenoreceptor agonist bronchodilator, an anticholinergic, a mucolytic agent, hypertonic saline and other drugs for treating Paramyxoviridae virus infections; or mixtures thereof. 3. The method of claim 2 wherein the at least one other therapeutic agent is ribavirin, palivizumab, motavizumab, RSV-IGIV, MEDI-557, A-60444, MDT-637 or BMS-433771 or mixtures thereof. 4. The method of claim 1 wherein the Paramyxoviridae infection is caused by a type 1 or 3 Human parainfluenza virus. 5. The method of claim 1 wherein the Paramyxoviridae infection is caused by a Pneumovirinae virus. 6. The method of claim 1 wherein the Paramyxoviridae infection is caused by a Human respiratory syncytial virus. 7. The method of claim 1 comprising administering the compound of Formula or a pharmaceutically acceptable salt thereof. 8. The method of claim 1 comprising administering the compound of Formula
Assignees
Inventors
Classifications
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
containing six-membered rings with nitrogen as a ring hetero atom · CPC title
having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10696679B2 cover?
- Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus in…
- Who is the assignee on this patent?
- Gilead Sciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).